Bayer to Target Cardio-Kidney-Metabolic Disease in Developing New Treatments
Bayer’s late-stage clinical development team, led by cardiologist Dr. Maria Borentain, is focusing on the interconnected nature of heart, kidney, and metabolic diseases in their new research initiatives. These efforts aim to shift traditional treatment boundaries, particularly in Asia, where aging populations are increasingly affected by these health issues.
Dr. Borentain explained that heart failure often causes complications in kidney function, and vice versa. This cyclical relationship, she noted, presents an opportunity for healthcare professionals to treat multiple conditions simultaneously. Historically, cardiologists managed heart failure separately from nephrologists dealing with kidney disease, and endocrinologists treating metabolic conditions. The company now encourages a holistic approach, urging doctors to consider how conditions like heart failure affect kidney health.
Bayer has a significant commitment to clinical trials in Asia, with approximately 26% of participants recruited from the region, which is notably higher than many other pharmaceutical companies. This focus stems from Bayer’s established relationships with healthcare providers and the company’s in-house clinical operations team that works directly with investigators at trial sites.
According to Dr. Borentain, as societies age, the importance of maintaining both cardiovascular and renal health becomes paramount for promoting independent living among seniors. She highlights the need to integrate brain health into future considerations for holistic health strategies, as cognitive health is vital for maintaining overall independence and quality of life.
Looking to the future, Bayer is exploring innovative treatments, including a new Factor XIa inhibitor designed for secondary stroke prevention. This medication aims to reduce the risk of recurrent strokes without increasing the chance of bleeding—a major concern among both patients and physicians. Current treatments often carry a stigma due to their bleeding risks, leading to underutilization.
Dr. Borentain also emphasized the role of education and the potential for artificial intelligence to improve patient care. As healthcare demands grow, AI can assist in disseminating trusted information and connecting patients with healthcare providers more effectively, especially through telehealth platforms.
The U.S. FDA has recently approved Bayer’s asundexian (Sunharbo), marking it as the first oral Factor XIa inhibitor for adult patients post-non-cardioembolic ischemic stroke or transient ischemic attack. This decision is expected to significantly alter treatment protocols in secondary stroke prevention.
